Switch to anabolics driving osteoporosis market growth
A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic drugs will prove the key driver in the global osteoporosis market, states research and consulting firm GlobalData.
The new report forecasts that the combined osteoporosis therapeutics market of the USA, France, Germany, Italy, Spain, the UK, Japan, China and India will reach a value of $8 billion in 2022 from just under $6 billion in 2012, including both branded and generic products.
Six major osteoporosis drugs will lose patent protection over the forecast period, which would strangle market growth if it were not for the introduction of several anabolic alternatives with the potential to become market leaders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze